Three big win­ners from Ab­b­Vie's $8.7B Cerev­el deal: A drug­mak­er, a CEO and a SPAC

Ab­b­Vie’s $8.7 bil­lion deal for Cerev­el comes with some in­ter­est­ing sub­plots. The ac­qui­si­tion of course sets up Ab­b­Vie for life af­ter Hu­mi­ra, but it al­so …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER